INT28317

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 1989
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 14
Disease Relevance 4.57
Pain Relevance 1.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (NXT1) intracellular (NXT1) cytoplasm (NXT1)
Anatomy Link Frequency
urine 3
knee 2
joint 1
arms 1
NXT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Analgesic 10 96.20 Very High Very High Very High
Osteoarthritis 410 95.84 Very High Very High Very High
Pain 25 93.88 High High
gABA 2 61.12 Quite High
cva 3 41.52 Quite Low
tetrodotoxin 1 37.84 Quite Low
dexamethasone 21 7.64 Low Low
Arthritis 10 6.32 Low Low
cINOD 15 5.00 Very Low Very Low Very Low
Opioid 14 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypercalcemia 36 97.76 Very High Very High Very High
Osteoarthritis 410 95.84 Very High Very High Very High
Pain 23 93.88 High High
Osteophyte 20 93.80 High High
Osteoporosis 158 90.52 High High
Bone Cancer 13 88.60 High High
Malignant Neoplastic Disease 7 87.64 High High
Cancer 7 86.68 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 15 86.52 High High
Metastasis 1 85.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A nonapeptide Thr-Ile-Ile-Asn-Val-Lys-Cys-Thr-Ser (NTX1-9) and a decapeptide Met-Asn-Gly-Lys-Cys-Lys-Cys-Tyr-Asn-Asn (NTX30-39) corresponding to the N-terminal and C-terminal sequences respectively of Noxiustoxin (NTX) were synthesized by the solid phase method of Merrifield (1963).
Gene_expression (synthesized) of NTX1-9
1) Confidence 0.14 Published 1989 Journal J. Neural Transm. Section Abstract Doc Link 2746197 Disease Relevance 0 Pain Relevance 0.03
The release profiles of NTX and NTX/TA?
Gene_expression (profiles) of NTX
2) Confidence 0.11 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
The results showed that pH 5.5 and 8.5 produced faster release of NTX among the studied formulations.
Gene_expression (produced) of NTX
3) Confidence 0.09 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
The release profiles of NTX and NTX/TA?
Gene_expression (profiles) of NTX
4) Confidence 0.05 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2948935 Disease Relevance 0 Pain Relevance 0
Changes in serum or urine levels of bALP, PINP, DKK-1, NTX-I, PTH and calcium were analyzed by comparison of the value of each marker at a given time point with the same marker pre-treatment using a Wilcoxon signed rank test.
Gene_expression (levels) of NTX-I in urine
5) Confidence 0.03 Published 2010 Journal European Journal of Haematology Section Body Doc Link PMC2970902 Disease Relevance 0 Pain Relevance 0
Urine NTX-I was normalized to urine creatinine and expressed as relative values.
Gene_expression (expressed) of NTX-I in urine
6) Confidence 0.02 Published 2010 Journal European Journal of Haematology Section Body Doc Link PMC2970902 Disease Relevance 0 Pain Relevance 0
In particular, higher doses of risedronate (15 mg/day) strongly reduced urinary levels of CTX-II and NTX-I.
Gene_expression (levels) of NTX-I
7) Confidence 0.02 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.46 Pain Relevance 0.23
Both RCTs showed risedronate treatment reduced urinary levels of CTX-II and NTX-I,8,9 and a subanalysis study of the RCT (KOSTAR) by Garnero, et al.11 revealed that urinary levels of CTX-II, but not NTX-I, reached after 6 months of risedronate treatment were associated with radiological progression of knee OA at 24 months.
Gene_expression (levels) of NTX-I in knee associated with osteoarthritis
8) Confidence 0.02 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.68 Pain Relevance 0.31
Both RCTs showed risedronate treatment reduced urinary levels of CTX-II and NTX-I,8,9 and a subanalysis study of the RCT (KOSTAR) by Garnero, et al.11 revealed that urinary levels of CTX-II, but not NTX-I, reached after 6 months of risedronate treatment were associated with radiological progression of knee OA at 24 months.
Gene_expression (levels) of NTX-I in knee associated with osteoarthritis
9) Confidence 0.02 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.58 Pain Relevance 0.26
Another subanalysis study by Garnero, et al.11 (the North America and European Union arms, n = 1,885) revealed that urinary levels of CTX-II and NTX-I decreased with risedronate treatment in a dose-dependent manner (Fig. 2).
Gene_expression (levels) of NTX-I in arms
10) Confidence 0.02 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.42 Pain Relevance 0.23
A larger RCT (n = 1,896, study period 2 years) by Bingham, et al.9 showed that risedronate at any doses (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) reduced urinary levels of CTX-II and NTX-I, but did not improve WOMAC scores, PGA scores, average number of days, and number of pills of analgesic medication taken per week, joint space width, and osteophyte development.
Gene_expression (levels) of NTX-I in joint associated with osteophyte and analgesic
11) Confidence 0.02 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2824859 Disease Relevance 0.76 Pain Relevance 0.32
Bone resorption markers measured included urinary calcium (uCa), hydroxyproline (Hyp), and the collagen breakdown products: NTx, Crosslaps and Free Dpd.
Gene_expression (products) of NTx
12) Confidence 0.02 Published 1997 Journal Ann. Oncol. Section Body Doc Link 9496390 Disease Relevance 0.25 Pain Relevance 0
To evaluate bone resorption, we measured urine NTX-I (Ostex International, Seattle, WA, USA) by competitive enzyme immunoassay techniques. bALP, PINP, DKK-1 and NTX-I were all analyzed in duplicates.
Gene_expression (bALP) of NTX-I in urine associated with hypercalcemia
13) Confidence 0.01 Published 2010 Journal European Journal of Haematology Section Body Doc Link PMC2970902 Disease Relevance 0.25 Pain Relevance 0
At baseline, 80-95% of patients showed elevated urinary pyridinoline, deoxypyridinoline, Osteomark NTx and serum ICTP levels, whereas only 35% of patients had elevated urinary CrossLaps excretion rates.
Gene_expression (levels) of Osteomark NTx
14) Confidence 0.01 Published 1998 Journal Clin. Chem. Lab. Med. Section Abstract Doc Link 9877095 Disease Relevance 1.16 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox